Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 2, 2008, Pages 329-335

  Bucki, Robert ^a   Namiot, Dorota B ^b   Namiot, Zbigniew ^b   Savage, Paul B ^c   Janmey, Paul A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^c Brigham Young University   (United States)

Author keywords

Antibacterial peptides; hCAP 18; Neuraminidase; WLBU2

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; ANTIMICROBIAL CATIONIC PEPTIDE WLBU2; ANTIMICROBIAL CATIONIC STEROID CSA 13; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; DNA; F ACTIN; LECTIN; MUCIN; POLYPEPTIDE ANTIBIOTIC AGENT; RHODAMINE; SIALIC ACID; SIALIDASE;

ADULT; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; ASSAY; BACTERICIDAL ACTIVITY; BINDING KINETICS; CONTROLLED STUDY; COW; DRUG STRUCTURE; ESCHERICHIA COLI; FLUOROMETRY; HUMAN; IMMUNOBLOTTING; ISOTOPE LABELING; MICROSCOPY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; SALIVA ANALYSIS; SUBMANDIBULAR GLAND;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; COLONY COUNT, MICROBIAL; HUMANS; IMMUNOBLOTTING; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MUCINS; SALIVA; STEROIDS;

EID: 47249162101     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn176     Document Type: Article

References (48)

1. Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. Clin Microbiol Rev 2006; 19: 491-511.
2. Dale BA, Tao R, Kimball JR et al. Oral antimicrobial peptides and biological control of cades. BMC Oral Health 2006; 6 Suppl 1: S13.
3. Bucki R, Levental I, Janmey PA. Antibacterial peptides - a bright future or a false hope. Anti-Infective Agents Med Chem 2007; 6: 175-84.
4. Frohm M, Agerberth B, Ahangari B et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 1997; 272: 15258-63.
5. Chromek M, Slamova Z, Bergman P et al. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat Med 2006; 12: 636-41.
6. Bals R, Wilson JM. Cathelicidins - a family of multifunctional antimicrobial peptides. Cell Mol Life Sci 2003; 60: 711-20.
7. Murakami M, Ohtake T, Dorschner RA et al. Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva. J Dent Res 2002; 81: 845-50.
8. Oppenheim FG, Xu T, McMillian FM et al. Histatins, a novel family of histidine-dch proteins in human parotid secretion: Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J Biol Chem 1988; 263: 7472-7.
9. Ganz T, Selsted ME, Szklarek D et al. Defensins: Natural peptide antibiotics of human neutrophils. J Clin Invest 1985; 76: 1427-35.
10. Sorensen OE, Follin P, Johnsen AH et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001; 97: 3951-9.
11. Devine DA. Antimicrobial peptides in defence of the oral and respiratory tracts. Mol Immunol 2003; 40: 431-43.
12. Ouhara K, Komatsuzawa H, Yamada S et al. Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, β-defensins and LL37, produced by human epithelial cells. J Antimicrob Chemother 2005; 55: 888-96.
13. Tjabringa GS, Aarbiou J, Ninaber DK et al. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J Immunol 2003; 171: 6690-6.
14. Nell MJ, Tjabringa GS, Wafelman AR et al. Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application. Peptides 2006; 27: 649-60.
15. Elssner A, Duncan M, Gavrilin M et al. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1β processing and release. J Immunol 2004; 172: 4987-94.
16. Schaller-Bals S, Schulze A, Bals R. Increased levels of antimicrobial peptides in tracheal aspirates of newborn infants during infection. Am J Respir Crit Care Med 2002; 165: 992-5.
17. Putsep K, Carlsson G, Boman HG et al. Deficiency of antibacterial peptides in patients with morbus Kostmann: An observation study. Lancet 2002; 360: 1144-9.
18. Carlsson G, Wahlin YB, Johansson A et al. Periodontal disease in patients from the original Kostmann family with severe congenital neutropenia. J Periodontol 2006; 77: 744-51.
19. Dommett R, Zilbauer M, George JT et al. Innate immune defence in the human gastrointestinal tract. Mol Immunol 2005; 42: 903-12.
20. Tao R, Jurevic RJ, Coulton KK et al. Salivary antimicrobial peptide expression and dental caries experience in children. Antimicrob Agents Chemother 2005; 49: 3883-8.
21. Dodds MW, Johnson DA, Yeh CK. Health benefits of saliva: A review. J Dent 2005; 33: 223-33.
22. Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 2006; 86: 245-78.
23. Nell MJ, Tjabringa G, Vonk MJ et al. Bacterial products increase expression of the human cathelicidin hCAP-18/LL-37 in cultured human sinus epithelial cells. FEMS Immunol Med Microbiol 2004; 42: 225-31.
24. Weiner DJ, Bucki R, Janmey PA. The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin. Am J Respir Cell Mol Biol 2003; 28: 738-45.
25. Felgentreff K, Beisswenger C, Griese M et al. The antimicrobial peptide cathelicidin interacts with airway mucus. Peptides 2006; 27: 3100-6.
26. Herasimenka Y, Benincasa M, Mattiuzzo M et al. Interaction of antimicrobial peptides with bacterial polysaccharides from lung pathogens. Peptides 2005; 26: 1127-32.
27. Ding B, Guan Q, Walsh JP et al. Correlation of the antibacterial activities of cationic peptide antibiotics and cationic steroid antibiotics. J Med Chem 2002; 45: 663-9.
28. Henke MO, Renner A, Huber RM et al. MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions. Am J Respir Cell Mol Biol 2004; 31: 86-91.
29. Arana Mde J, Vallespi MG, Chinea G et al. Inhibition of LPS-responses by synthetic peptides derived from LBP associates with the ability of the peptides to block LBP-LPS interaction. J Endotoxin Res 2003; 9: 281-91.
30. Bucki R, Pastore JJ, Randhawa P et al. Antibacterial activities of rhodamine B-conjugated gelsolin-derived peptides compared to those of the antimicrobial peptides cathelicidin LL37, magainin II, and melittin. Antimicrob Agents Chemother 2004; 48: 1526-33.
31. Giacometti A, Cirioni O, Greganti G et al. In vitro activities of membrane-active peptides against Gram-positive and Gram-negative aerobic bacteria. Antimicrob Agents Chemother 1998; 42: 3320-4.
32. Nakamura T, Takada N, Tonozuka T et al. Binding properties of Clostridium botulinum type C progenitor toxin to mucins. Biochim Biophys Acta 2007; 1770: 551-5.
33. Oren Z, Lerman JC, Gudmundsson GH et al. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: Relevance to the molecular basis for its non-cell-selective activity. Biochem J 1999; 341: 501-13.
34. Shugars DC. Endogenous mucosal antiviral factors of the oral cavity. J Infect Dis 1999; 179 Suppl 3: S431-5.
35. Vitorino R, Lobo MJ, Duarte JA et al. Analysis of salivary peptides using HPLC-electrospray mass spectrometry. Biomed Chromatogr 2004; 18: 570-5.
36. Butler JC, Angelini T, Tang JX et al. Ion multivalence and like-charge polyelectrolyte attraction. Phys Rev Lett 2003; 91 283-301.
37. Chin JN, Rybak MJ, Cheung CM et al. Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 1268-73.
38. Bucki R, Sostarecz AG, Byfield FJ et al. Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum. J Antimicrob Chemother 2007; 60: 535-45.
39. Chin JN, Jones RN, Sader HS et al. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. J Antimicrob Chemother 2008; 61: 365-70.
40. Corfield AP, Carroll D, Myerscough N et al. Mucins in the gastro-intestinal tract in health and disease. Front Biosci 2001; 6: D1321-57.
41. Wiggins R, Hicks SJ, Soothill PW et al. Mucinases and sialidases: their role in the pathogenesis of sexually transmitted infections in the female genital tract. Sex Transm Infect 2001; 77: 402-8.
42. Vimr E, Lichtensteiger C. To sialylate, or not to sialylate: That is the question. Trends Microbiol 2002; 10: 254-7.
43. Koczulla R, von Degenfeld G, Kupatt C et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 2003; 111: 1665-72.
44. Malmsten M, Davoudi M, Walse B. Antimicrobial peptides derived from growth factors. Growth Factors 2007; 25: 60-70.
45. Murakami M, Lopez-Garcia B, Braff M et al. Postsecretory processing generates multiple catholicidins for enhanced topical antimicrobial defense. J Immunol 2004; 172: 3070-7.
46. Li X, Li Y, Han H et al. Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region. J Am Chem Soc 2006; 128 5776-85.
47. Hase K, Murakami M, Iimura M et al. Expression of LL-37 by human gastric epithelial cells as a potential host defense mechanism against Helicobacter pylori. Gastroenterology 2003; 125: 1613-25.
48. Travis SM, Anderson NN, Forsyth WR et al. Bactericidal activity of mammalian cathelicidin-derived peptides. Infect Immun 2000; 68 2748-55.